Immunovant Inc Sustainability Reports
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for people with autoimmune diseases. Its pipeline primarily centers on novel inhibitors of the neonatal fragment crystallizable receptor (FcRn), such as imeroprubart (IMVT-1402).
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00P5MC0R7
4 reports from 2021 to 2025
Company Profile
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for people with autoimmune diseases. Its pipeline primarily centers on novel inhibitors of the neonatal fragment crystallizable receptor (FcRn), such as imeroprubart (IMVT-1402).
Reports
4 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
